scholarly journals Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity

Author(s):  
Chun-Yan Zheng ◽  
Sze-Kwan Lam ◽  
Yuan-Yuan Li ◽  
James Ho
2020 ◽  
Vol 11 (4) ◽  
pp. 1015-1025
Author(s):  
Chun‐cheng Hao ◽  
Jia‐ning Luo ◽  
Cui‐yang Xu ◽  
Xin‐yu Zhao ◽  
Zhen‐bin Zhong ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Meng-Hang Yang ◽  
Ke-Jie Chang ◽  
Bing Li ◽  
Wan-Sheng Chen

Small-cell lung cancer (SCLC) is a highly malignant type of lung cancer with no effective second-line chemotherapy drugs. Arsenic trioxide (As2O3) was reported to exert antiangiogenesis activities against lung cancer and induce poor development of vessel structures, similar to the effect observed following the blockade of Notch signaling. However, there are no direct evidences on the inhibitory effects of As2O3 on tumor growth and angiogenesis via blockade of Notch signaling in SCLC. Here, we found that As2O3 significantly inhibited the tumor growth and angiogenesis in SCLC and reduced the microvessel density. As2O3 disturbed the morphological development of tumor vessels and downregulated the protein levels of delta-like canonical Notch ligand 4 (Dll4), Notch1, and Hes1 in vivo. DAPT, a Notch signaling inhibitor, exerted similar effects in SCLC. We found that both As2O3 treatment and Notch1 expression knockdown resulted in the interruption of tube formation by human umbilical vein endothelial cells (HUVECs) on Matrigel. As2O3 had no effects on Dll4 level in HUVECs but significantly inhibited the expression of Notch1 and its downstream gene Hes1 regardless of Dll4 overexpression or Notch1 knockdown. These findings suggest that the antitumor activity of As2O3 in SCLC was mediated via its antiangiogenic effect through the blockade of Notch signaling, probably owing to Notch1 targeting.


Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1869
Author(s):  
Laia Coll-SanMartin ◽  
Veronica Davalos ◽  
David Piñeyro ◽  
Margalida Rosselló-Tortella ◽  
Alberto Bueno-Costa ◽  
...  

The alteration of RNA modification patterns is emerging as a common feature of human malignancies. If these changes affect key RNA molecules for mRNA translation, such as transfer RNA, they can have important consequences for cell transformation. TRIT1 is the enzyme responsible for the hypermodification of adenosine 37 in the anticodon region of human tRNAs containing serine and selenocysteine. Herein, we show that TRIT1 undergoes gene amplification-associated overexpression in cancer cell lines and primary samples of small-cell lung cancer. From growth and functional standpoints, the induced depletion of TRIT1 expression in amplified cells reduces their tumorigenic potential and downregulates the selenoprotein transcripts. We observed that TRIT1-amplified cells are sensitive to arsenic trioxide, a compound that regulates selenoproteins, whereas reduction of TRIT1 levels confers loss of sensitivity to the drug. Overall, our results indicate a role for TRIT1 as a small-cell lung cancer-relevant gene that, when undergoing gene amplification-associated activation, can be targeted with the differentiation agent arsenic trioxide.


2015 ◽  
Vol 10 (2) ◽  
pp. 805-809 ◽  
Author(s):  
TOSHIHIRO SUZUKI ◽  
KENICHI ISHIBASHI ◽  
ATSUSHI YUMOTO ◽  
KAZUTO NISHIO ◽  
YUKI OGASAWARA

Lung Cancer ◽  
2013 ◽  
Vol 82 (2) ◽  
pp. 222-230 ◽  
Author(s):  
Chun-yan Zheng ◽  
Sze-kwan Lam ◽  
Yuan-yuan Li ◽  
Bonnie Mei-wah Fong ◽  
Judith Choi-wo Mak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document